Author [ Title] Type Year
Filters: Author is Litzow, Mark R [Clear All Filters]
Blinatumomab for Acute Lymphoblastic Leukemia Relapse After Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2019.
CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells from MDS patients against primary MDS and MDSC CD33+ targets. Blood. 2014.
Clinical utilization of Chimeric Antigen Receptors T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL) - an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transpl. Biol Blood Marrow Transplant. 2018.
Comparative analysis of calcineurin-inhibitor-based methotrexate and mycophenolate mofetil-containing regimens for prevention of Graft-versus-Host Disease after reduced intensity conditioning allogeneic transplantation. Biol Blood Marrow Transplant. 2018.
Comparison of Pretransplant Prediction Models for Non-Relapse Mortality in Patients with Myelofibrosis Undergoing Allogeneic Stem Cell Transplantation. Transplant Cell Ther. 2023.
Correlation of Pain and Fluoride Concentration in Allogeneic Hematopoietic Stem Cell Transplant Recipients on Voriconazole. Biol Blood Marrow Transplant. 2015.
The Effect of Aging and Pre-Donation Comorbidities on the Related PBSC Donor Experience: A Report from the Related Donor Safety Study (RDSafe). Biol Blood Marrow Transplant. 2018.
Factors predicting survival following alloSCT in patients with therapy-related AML and MDS: a multicenter study. Bone Marrow Transplant. 2023.
Health-Related Quality-of-Life Comparison of Adult Related and Unrelated HSC Donors: An RDSafe Study. Biol Blood Marrow Transplant. 2020.
Impact of Alemtuzumab Therapy and Route of Administration in T-Prolymphocytic Leukemia: A Single-Center Experience. Clin Lymphoma Myeloma Leuk. 2015.
Impact of Donor Age on Allogeneic Hematopoietic Cell Transplantation Outcomes in Older Adults with Acute Myeloid Leukemia. Transplant Cell Ther. 2023.
Impact of hospital hospitality house programs on quality of life and mood of patients and caregivers after hematopoietic stem cell transplant. Hematol Oncol Stem Cell Ther. 2018.
Incorporation of extracorporeal photopheresis into a reduced intensity conditioning regimen in myelodysplastic syndrome and aggressive lymphoma: results from ECOG 1402 and 1902. Transfusion. 2020.
Intensive versus less-intensive antileukemic therapy in older adults with acute myeloid leukemia: A systematic review. PLoS One. 2021;16(3):e0249087.
Late effects after ablative allogeneic stem cell transplantation for adolescent and young adult acute myeloid leukemia. Blood Adv. 2020;4(6):983-992.
Pericardial effusion as a purported manifestation of graft versus host disease following allogeneic hematopoietic cell transplantation. Transplant Cell Ther. 2023..
Peripheral Blood versus Bone Marrow from Unrelated Donors: Bone Marrow allografts have improved Long-term Overall and Graft-versus-Host Disease, Relapse-Free Survival. Biol Blood Marrow Transplant. 2018.
A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Myelodysplastic Syndromes Patients. Biol Blood Marrow Transplant. 2020.
Reduced intensity conditioning allogeneic hematopoietic stem cell transplantation in VEXAS syndrome: Data from a prospective series of patients. Am J Hematol. 2022.